Can you provide the last earnings date for BIOCRYST PHARMACEUTICALS INC?
BIOCRYST PHARMACEUTICALS INC (BCRX) last reported earnings on 2/26/2026.
BIOCRYST PHARMACEUTICALS INC (BCRX) Earnings History & Surprises
NASDAQ:BCRX • US09058V1035
Current stock price
9.4 USD
-0.26 (-2.69%)
At close:
9.45 USD
+0.05 (+0.53%)
Pre-Market:
BCRX Earnings overview
Past quarterly earnings results for BIOCRYST PHARMACEUTICALS INC (BCRX), including EPS and revenue actuals, analyst estimates, and surprise percentages. This page focuses on historical performance (not forecasts).
Earnings Snapshot
Next Earnings Date
Upcoming- Release Date
- May 4, 2026
- Period
- Q1 / 2026
- EPS Estimate
- $0.05
- Revenue Estimate
- 154.7M
Last Reported
Most Recent- Release Date
- Feb 26, 2026
- Period
- Q4 / 2025
- EPS Reported
- $0.01
- EPS Surprise
- -74.12%
- Revenue Surprise
- 6.52%
Beat Rate
Last 8 Quarters 69%
EPS and Revenue beats vs estimates
Quarterly Earnings Historical Results
EPS & Revenue History (in USD): Actual vs estimated values, surprises, q2q growth and acceleration numbers quarterly history.
| Quarter | EPS | EPS Est | EPS Surprise | EPS Q2Q | Revenue | Revenue Est | Revenue Surprise | Revenue Q2Q |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 0.01 | 0.04 | -74.12% | 107.69% | 162.575M | 152.63M | 6.52% | 23.60% |
| Q3 2025 | 0.06 | 0.04 | 67.02% | 185.71% | 159.395M | 166.23M | -4.11% | 36.14% |
| Q2 2025 | 0.04 | 0.01 | 180.11% | 166.67% | 163.353M | 152.73M | 6.96% | 49.41% |
| Q1 2025 | 0.00 | -0.07 | 100.00% | 100.00% | 145.534M | 129.4M | 12.47% | 56.89% |
| Q4 2024 | -0.13 | -0.06 | -123.60% | 53.57% | 131.534M | 132.75M | -0.92% | 40.83% |
| Q3 2024 | -0.07 | -0.07 | -6.50% | 63.16% | 117.085M | 114.75M | 2.03% | 34.98% |
| Q2 2024 | -0.06 | -0.18 | 66.23% | 75.00% | 109.332M | 100.29M | 9.02% | 32.54% |
| Q1 2024 | -0.17 | -0.22 | 20.98% | 39.29% | 92.761M | 87.317M | 6.23% | 34.87% |
| Q4 2023 | -0.28 | -0.25 | -12.50% | 26.32% | 93.401M | 91.807M | 1.74% | 17.41% |
| Q3 2023 | -0.19 | -0.24 | 20.19% | 17.39% | 86.742M | 87.673M | -1.06% | 14.39% |
| Q2 2023 | -0.24 | -0.23 | -3.06% | 25.00% | 82.491M | 82.606M | -0.14% | 25.88% |
| Q1 2023 | -0.28 | -0.30 | 8.14% | 30.00% | 68.778M | 73.111M | -5.93% | 37.78% |
| Q4 2022 | -0.38 | -0.17 | -120.09% | -280.00% | 79.55M | 77.149M | 3.11% | 68.68% |
| Q3 2022 | -0.23 | -0.30 | 22.47% | 30.30% | 75.83M | 76.117M | -0.38% | 85.00% |
| Q2 2022 | -0.32 | -0.35 | 8.62% | -33.33% | 65.53M | 65.594M | -0.10% | 31.16% |
| Q1 2022 | -0.40 | -0.37 | -7.10% | -11.11% | 49.92M | 52.387M | -4.71% | 161.91% |
| Q4 2021 | -0.10 | -0.31 | 67.82% | 70.59% | 47.16M | 50.53M | -6.67% | 1,073.13% |
| Q3 2021 | -0.33 | -0.30 | -9.92% | -26.92% | 40.99M | 40.885M | 0.26% | 571.97% |
| Q2 2021 | -0.24 | -0.25 | 2.26% | - | 49.96M | 29.245M | 70.83% | 1,640.77% |
| Q1 2021 | -0.36 | -0.28 | -29.80% | -50.00% | 19.06M | 9.067M | 110.21% | 295.44% |
| Q4 2020 | -0.34 | -0.26 | -32.96% | - | 4.02M | 15.038M | -73.27% | - |
| Q3 2020 | -0.26 | -0.26 | 0.16% | - | 6.1M | 3.677M | 65.90% | - |
| Q2 2020 | -0.24 | -0.26 | 7.89% | - | 2.87M | 2.301M | 24.73% | - |
| Q1 2020 | -0.24 | -0.25 | 3.04% | - | 4.82M | 4.376M | 10.15% | - |
Notes
- EPS and Revenue values are non-GAAP when available, otherwise GAAP.
- Surprise % is (Actual - Estimate) / |Estimate|. Green indicates positive surprise, red negative.
- Q2Q % is quarter-over-quarter growth. Green indicates growth, red indicates decline.
- Green right border indicates acceleration for sales or earnings growth. Acceleration is the case when the current Q2Q is above the previous Q2Q.
Earnings Q2Q Performance Trends
EPS Historical Q2Q growth and Acceleration
Revenue Historical Q2Q growth and Acceleration
Surprise distribution (Last 4 Quarters)
EPS beat statistics
EPS beat (4)
3
Average EPS beat (4)
68.25%
Max EPS beat (4)
180.11%
Min EPS beat (4)
-74.12%
Revenue beat statistics
Revenue beat (4)
3
Average Revenue beat (4)
5.46%
Max Revenue beat (4)
12.47%
Min Revenue beat (4)
-4.11%
Analysis
In the last 4 quarters, BCRX has beaten EPS estimates in 3 out of 4 releases
BCRX has beaten revenue estimates in 3 out of the last 4 releases
In the last 4 quarters, BCRX has beaten the EPS estimates by 68.3% on average.
In the last 4 quarters, BCRX has beaten the revenue estimates by 5.5% on average.
Related analysis
BIOCRYST PHARMACEUTICALS INC / BCRX Earnings FAQ
Did BCRX stock beat earnings estimates in the most recent quarter?
BIOCRYST PHARMACEUTICALS INC (BCRX) missed EPS estimates and beat revenue estimates in the most recent quarter.
How often does BIOCRYST PHARMACEUTICALS INC (BCRX) beat earnings estimates?
In the last 4 quarters, BIOCRYST PHARMACEUTICALS INC (BCRX) has beaten EPS estimates in 3 out of 4 releases.